期刊文献+

HPLC测定参松养心胶囊中人参皂苷Rb_1的含量 被引量:9

Determination of Ginsenoside Rb_1 in Shensong Yangxin Capsules by HPLC
原文传递
导出
摘要 目的:建立高效液相色谱(HPLC)测定参松养心胶囊中人参皂苷Rb1含量的方法,为参松养心胶囊的质量标准控制提供理论依据。方法:样品经甲醇回流提取2 h,水饱和正丁醇萃取,氨试液洗涤。采用Agilent 1200RRLC高分离度快速液相色谱仪,waters XTERRAMS C18(4.6 mm×250 mm,5μm)色谱柱,柱温室温,流动相乙腈-水(53∶47),流速1.0 mL.min-1,检测波长203 nm,进样体积40μL。结果:人参皂苷Rb1进样量在5.0~200.0 mg.L-1与峰面积呈良好线性关系(r=0.998 9);平均回收率为100.31%,RSD 1.98%。结论:实验所建立的方法专属性强,准确度高,重复性好,可作为参松养心胶囊质量控制。 Objective: To establish a method for measuring the content of Ginsenoside Rb1 in Shensong Yangxin capsules by HPLC, in order to provide theoretical basis for the quality standards of Shensong Yangxin capsules. Method: The Ginsenoside Rb1 from Shensong Yangxin capsules was extracted by methanol reflux extraction 2 h, and then extracted by water-saturated n-butanol with, ammonia solution washing. The content of Ginsenoside Rb1 in Shensong Yangxin capsules was measured by HPLC, the instrument and chromatographic conditions was Agilenill00 high-performance liquid chromatograph, waters XTERRA MS C18 (4.6 mm × 250 mm, 5 μm), column temperature : room temperature ; mobile phase : acetonitrile-water (53 : 47) ; flow rate 1.0 mL·min^-1 ; detection wavelength 203 nm; injection volume 40 μL. Result: The Ginsenoside Rb1 within the range of 5.0-200,0 mg· L^-1 was linear with the peak area, r 0.998 9; the average recovery was 100.31%, RSD 1.98%. Conclusion: The established method has strong specificity, high accuracy and good reproducibility, it can be used as quality control of Shensong Yangxin capsules.
作者 莫炫永
出处 《中国实验方剂学杂志》 CAS 北大核心 2012年第12期112-114,共3页 Chinese Journal of Experimental Traditional Medical Formulae
关键词 高效液相色谱 参松养心胶囊 人参皂苷RB1 HPLC Shensong Yangxin capsuless ginsenoside Rb1
  • 相关文献

参考文献10

二级参考文献31

  • 1李晶晶,徐国钧,金蓉鸾,徐珞珊.人参与西洋参的皂甙成分分析[J].中国中药杂志,1995,20(4):197-199. 被引量:28
  • 2李宁,吴相锋,马克娟,赵新然,吴以岭,浦介麟.参松养心胶囊对心室肌细胞钾通道的影响[J].疑难病杂志,2007,6(3):133-137. 被引量:174
  • 3冯埃生,邹汉法,汪海林,李瑞江,王学政,张玉奎.影响高效液相色谱/挥发激光散射检测器检测性能基本因素的考察[J].药物分析杂志,1996,16(6):414-417. 被引量:102
  • 4关于印发《中药注射剂指纹图谱研究的技术要求》的通知[J].中国药品标准,2000,1(4):3-3.
  • 5A.希尼维斯.心血管疾病治疗学[M].北京:人民卫生出版社,1993:466.
  • 6[1]Dou DQ,Hou WB,Chen YJ.Studies on the characteristic constituents of Chinese ginseng and American ginseng[J].Planta Med.,1998.64:555-556.
  • 7Prystowsky E N,Beson D W Jr,Fuster V,et al.Management of ptients with atrial fibrillation:a statement for healthcare professionals from the subcommittee on electrocardiography and electrophysiology[J].Am Heart Assoc Circulation,1996,93:1262.
  • 8Prystowsky E N.Management of atrial fibrillation;therapeutic options and clinical decisions[J].Am JCardiol,2000,85:3D.
  • 9Ewy G A,Horan G Q,Piepoli M F,et al.The role of oralIC antiarrhythmic drugs in terminating atrial fribrillation[J].Curr Opin Cardiol,1999,14:4.
  • 10Reiffel J A.Drug choices in the treatment of atrialfibrillation[J].AM J Cardiol,2003,85:12D.

共引文献52

同被引文献72

引证文献9

二级引证文献46

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部